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Abstract
Autophagy is a double-edged sword in tumorigenesis and plays an important role in the resistance of cancer cells to
chemotherapy. S100A8 is a member of the S100 calcium-binding protein family and plays an important role in the drug
resistance of leukemia cells, with the mechanisms largely unknown. Here we report that S100A8 contributes to drug
resistance in leukemia by promoting autophagy. S100A8 level was elevated in drug resistance leukemia cell lines relative to
the nondrug resistant cell lines. Adriamycin and vincristine increased S100A8 in human leukemia cells, accompanied with
upregulation of autophagy. RNA interference-mediated knockdown of S100A8 restored the chemosensitivity of leukemia
cells, while overexpression of S100A8 enhanced drug resistance and increased autophagy. S100A8 physically interacted with
the autophagy regulator BECN1 and was required for the formation of the BECN1-PI3KC3 complex. In addition, interaction
between S100A8 and BECN1 relied upon the autophagic complex ULK1-mAtg13. Furthermore, we discovered that
exogenous S100A8 induced autophagy, and RAGE was involved in exogenous S100A8-regulated autophagy. Our data
demonstrated that S100A8 is involved in the development of chemoresistance in leukemia cells by regulating autophagy,
and suggest that S100A8 may be a novel target for improving leukemia therapy.
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Introduction
Autophagy is a catabolic process involving the degradation of
intracellular aggregated or misfolded proteins, and damaged
organelles through lysosomal machinery in response to stress or
starvation [1,2]. Deregulation of autophagy is implicated in several
human diseases including cancers. Depending on the type of
tumor and stage of disease, autophagy induces both tumor cell
survival and death during the initiation, progression, maturation
and maintenance of cancer [3].
It has been well documented that autophagy plays an important
role in the resistance of cancer cells to chemotherapy [4].
Consequently, pharmacological inhibition of autophagy enhances
chemotherapeutic drug-induced cytotoxicity and apoptosis in
leukemia cells [4–6]. We recently found that damage associated
molecular pattern molecules (DAMPs) such as high mobility group
box 1 (HMGB1) contribute to chemotherapy resistance though
upregulating autophagy in leukemia [7]. S100A8 (also designated
MRP8 or calgranulin A) is a member of DAMPs, differentially
expressed in a wide variety of cell types and abundant in myeloid
cells [8,9]. S100A8 is involved in the progression of various
cancers, including leukemia, and induces cell death by functional
linkage with Bcl-2 family members [10–14]. We previously found
that the expression level of S100A8 correlates with poor clinical
outcomes in childhood acute myeloblastic leukemia (AML).
Accordingly, knockdown of S100A8 by siRNA-treated myeloid
leukemia cells showed sensitization to arsenic trioxide, accompa-
nied with the attenuation of autophagy and disassociation of the
BECN1-Bcl-2 complex [14]. The data suggest that S100A8
contributes to chemoresistance via regulating the autophagy in
leukemia.
In this study, we found that S100A8 enhances drug resistance
by upregulating autophagy through promoting the formation of
BECN1-PI3KC3 [PI3KC3, phosphatidylinositol 3-kinase class 3]




The antibodies against S100A8 and p62 were obtained from
Santa Cruz Biotechnology (Sana Cruz, CA, USA). The antibodies
to Actin, BECN1, PI3KC3, C-PARP, ULK1, Bcl-2 and P-ULK1
were from Cell Signaling Technology (Boston, MA, USA). The
antibodies to LC3 and TLR-4 were purchased from Abcam
(Cambridge, MA, USA). Anti-Atg7 antibody was from Novus
(Denver-Littleton, CO, USA). Vincristine (VCR), adriamycin
(ADM), rotenone (Rot), thenoyltrifluoroacetone (TTFA), antimy-
cin A (AA), E64D, anti-RAGE antibody and pepstatin were from
Sigma (Milpitas, CA, USA). Full-length human S100A8 cDNA
(pLPCX-S100A8) was a gift from Dr. RW Stam (Erasmus Medical
Center/Sophia Children’s Hospital, Netherlands). FITC-Annexin
V Apoptosis Detection kit and the Nuclear and Cytoplasmic
Protein Extraction kit were purchased form Beyotime Institute of
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Biotechnology (Beijing, China). S100A8 protein was obtained
from Novus Biologicals. Contaminating LPS was removed by
Triton X-114 extraction. LPS content was always below 0.5 ng/
mg protein, which did not cause an effect in our assays.
Cell culture
The human leukemia cell lines, K562 (chronic myeloid
leukemia cells), HL-60 (acute myeloid leukemia cells), MV-4-11
(biphenotypic B myelomonocytic leukemia cells), Jurkat (T-cell
acute lymphoblastic leukemia cells), and K562/A02 (multidrug
resistance K562) were from the American Type Culture Collec-
tion; HL-60/ADR (multidrug resistance HL-60) was from the
Institute of Hematology & Blood Diseases Hospital of Chinese
Academy of Medical Sciences & Peking Union Medical College.
Cells were cultured in RPMI-1640 medium supplemented with
10% heat-inactivated FBS and 2 mM glutamine in a humidified
incubator with 5% CO2 and 95% air.
Figure 1. S100A8 was elevated in drug resistance leukemia cells and chemotherapy agents induced S100A8 expression in leukemia
cells. (A) Protein level of S100A8 was analyzed by Western blotting in Jurkat, HL-60, K562 and MV4-11 cells (n = 3, *P,0.05). (B and C) S100A8 mRNA
level in leukemia cells was analyzed by real time RT-PCR (n = 3, *P,0.05 versus Jurkat cells in B and *P,0.05 versus HL-60 or K562 in C, Jurkat group
set as 1). (D) Basal LC3-I/II level was analyzed by Western blotting in leukemia cells (n = 3, *P,0.05 versus Jurkat cells ). (E and F) IC50 levels of
adriamycin (ADR) in Jurkat, K562, HL-60, MV-4-11, K562/A02, and HL-60/ADR cells (n = 3, *P,0.05 versus Jurkat cells in E, *P,0.05 versus HL-60 or
K562 in F). (G) Jurkat, HL-60, K562 and MV4-11 cells were treated with ADR (1 mg/ml), VCR (1 mg/ml) or As2O3 (5 mM) for 24 hours and S100A8 protein
level was analyzed by Western blotting (n = 3, *P,0.05 vs. UT, untreated group). AU, arbitrary unit. (H) Jurkat, HL-60, K562 and MV4-11 cells were
treated with ADR (1 mg/ml), vincristine (VCR, 1 mg/ml) or arsenic trioxide (As2O3, 5 mM) for 24 hours and S100A8 mRNA level was analyzed by real
time RT-PCR (n = 3, *P,0.05 versus control group, control group set as 1).
doi:10.1371/journal.pone.0097242.g001
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Figure 2. Suppression of S100A8 sensitized drug resistance leukemia cells to chemotherapy. (A) HL60/ADR and K562/A02 cells were
transfected with control shRNA or S100A8 shRNA for 48 hours. Protein and mRNA level of S100A8 was assayed by Western blot and real time RT-PCR,
respectively. (B) HL60/ADR and K562/A02 cells were transfected with control shRNA or S100A8 shRNA for 48 hours, then treated with adriamycin
S100A8 and Autophagy in Leukemia
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Cell viability assay
Cell viability was assessed by MTT assay. Briefly, leukemia cells
were seeded in 96-well plates (4000 cells/well) the day before
treatment. Following treatment with ADR for 72 h, 25 mL MTT
[3-(4,5-dimethylthiazol–2-yl)- 2,5-diphenyltetrazolium bromide;
Sigma] was added to each well and incubated for 3.5 h, followed
by the addition of 100 mL of N,Ndimethylformamide (D4551;
Sigma). The plates were left at room temperature overnight to
allow complete lysis of the cells, and read at 450 nm the following
day. Half-maximal inhibitory concentration (IC50) was calculated
using MS Excel, as previously described [15].
Western blot analysis
Cell lysates were prepared with cell lysis buffer [20 mmol/L
Tris-HCl, pH 7.5; 150 mmol/L NaCl; 1 mmol/L Na2EDTA;
1 mmol/L EGTA; 1% Triton; 2.5 mmol/L sodium pyrophos-
phate; 1 mmol/L b-glycerophosphate; 1 mmol/L Na3VO4;
1 mg/mL leupeptin; 1 mmol/L phenylmethylsulfonylfluoride
(PMSF); and 1 mmol/L PMSF], and cleared by centrifugation.
Total protein concentration was determined with the bicincho-
ninic acid assay Kit (Bio-Rad). Proteins were resolved on a
denaturing 10% SDS-PAGE gel and subsequently transferred to
polyvinylidene fluoride membranes via semidry transfer. The
membrane was blocked with 5% dried milk or 3% bovine serum
albumin in Tris-buffered saline and Tween 20 (10 mmol/L Tris,
pH 7.5; 100 mmol/L NaCl; and 0.1% Tween20), incubated with
primary antibodies, and then with horseradish peroxidase–
conjugated secondary antibodies. The signals were visualized by
enhanced chemiluminescence.
Quantitative real-time PCR
Total RNA was extracted using TRIzol (Invitrogen, USA)
according to the manufacturer’s instructions. Reverse transcription
(RT) was performed with 2 mg of total RNA with HiFi-MMLV
Enzyme Mix (CWbio, China). Twenty ng cDNA was subjected to
real-time quantitative PCR (TaqMan probes) for the evaluation of
the relative S100A8 mRNA, with beta actin as an internal control
with gene specific primers and fluorogenic probes (S100A8:
forward primer 59- CCTAACCGCTATAAAAAGGAG -39,
reverse primer 59- ATGATGCCCACGGACTTGCC -3, probe
59 FAM-CCTCTCAGCCCTGCATGTCTCTT -TAMRA 39;
ACTB: forward primer 59- GGCACCCAGCACAATGAAGA-3,
reverse primer 59-CGTCATACTCCTGCTTGCTG-39, probe
59FAM-CTGGAAGGTGGACAGCGAGGC-TAMRA 39.) in an
LightCycler 480 System (Roche). Quantification was determined
by the standard curve and 2-DDCt methods [15].
Immunoprecipitation analysis
Cells were lysed at 4uC in ice-cold radioimmunoprecipitation
assay lysis buffer (Millipore, Billerica, MA, USA). Cell lysates were
cleared by a brief centrifugation (12,000 g, 10 min). Protein
concentration in the supernatant was determined by bicinchoninic
acid assay. Before immunoprecipitation, equal amounts of proteins
were pre-cleared with Protein A or protein G agarose/sepharose
(Millipore) at 4uC for 3 h and subsequently incubated with various
irrelevant immunoglobulin-G or specific antibodies (5 mg/ml) in
the presence of protein A or G agarose/sepharose beads for 2 h or
overnight at 4uC with gently shaking. Following incubation,
agarose/sepharose beads were washed extensively with phosphate
buffered saline. Proteins were eluted by boiling in 26SDS sample
buffer before SDS–polyacrylamide gel electrophoresis and immu-
noblot analysis, as previously described [15,16].
Gene transfection and RNAi
Cells were transfected with S100A8 pLPCX constructs by
square-pulse electroporation at 600 V for 2 msec and cultured
under selection of neomycin (1 mg/ml; Gibco BRL, USA) and
puromycin (10 mg/ml; Sigma) in order to obtain a pure
population of transfected cells [13]. Lipofectamine 2000 Trans-
fection Reagent (Invitrogen) was used to transfect S100A8-
shRNA, BECN1-shRNA, PI3KC3-shRNA, ULK1-shRNA,
RAGE-shRNA, TLR4-shRNA and Atg7 shRNA (Sigma) [16].
As a control experiment, another S100A8-shRNA was obtained
from Gene Pharma (Shanghai, China).
Apoptosis assays
Apoptosis was assessed using the FITC Annexin V Apoptosis
Detection kit, which involves staining cells with Annexin V-FITC
(a phospholipid-binding protein that binds to disrupted cell
membranes) in combination with PI (a vital dye that binds to
DNA penetrating into apoptotic cells). Flow cytometric analysis
(FACS) was performed to determine the percentage of apoptotic
cells (Annexin V+/PI).
Electron microscopy
Leukemia cells were collected and fixed in 2.5% glutaraldehyde
for at least 3 h. Then cells were treated with 2% paraformaldehyde
at room temperature for 60 min, 0.1% glutaraldehyde in 0.1 M
sodium cacodylate for 2 h, post-fixed with 1% OsO4 for 1.5 h,
dehydrated with graded acetone, and embedded in Quetol 812.
Ultrathin sections were observed using a Hitachi H7500 electron
microscope (Tokyo, Japan) [17].
Immunofluorescence and confocal microscopy
Cells were collected, fixed and permeabilized with 0.3% triton
X-100 for 10 min, incubated with anti-LC3 for 1 h and then
FITC-conjugated Anti-LC3A/B antibody (Abcam, ab58610) for 1
h at room temperature. Cell nuclei were stained using ProLong
Gold Antifade Reagent with DAPI (Life Technologies). Samples
were examined under an Olympus FV1000 confocal microscope.
For evaluating tandem fluorescent LC3 puncta, cells were washed
with PBS, fixed with 4% paraformaldehyde, mounted with DAPI
and viewed under a confocal microscope [17].
Autophagy assays
To analyze autophagic flux, we monitored the formation of
autophagic vesicles by the mRFP–GFP–LC3 method (Invitrogen).
Due to the quenching of GFP in the acidic lysosomal environment
(ADR) and vincristine (VCR) for an additional 24 hours. Cell viability was analyzed by MTT. (C and D) HL60/ADR and K562/A02 cells were transfected
with control shRNA or S100A8 shRNA for 48 hours, treated with ADR (12.5 mg/mL), VCR (12.5 mg/mL) for additional 24 hours. Apoptosis was analyzed
by measuring positive percentage of Annexin V cells via flow cytometry (C; n = 3; *P,0.05); cleaved PARP was analyzed by Western blotting (D). (E)
HL60/ADR and K562/A02 cells were transfected with control shRNA or S100A8 shRNA for 48 hours, and then treated with ADR (12.5 mg/mL), VCR
(12.5 mg/mL) for additional 24 hours with or without ZVAD-FMK (20 mmol/L). Activation of caspase-3 was analyzed (n = 3; *P,0.05). (F) HL60/ADR
cells were transfected with control shRNA or S100A8 shRNA (from Gene Pharma, China) for 48 hours and then treated with ADR (12.5 mg/mL), VCR
(12.5 mg/mL) for 24 hours. S100A8 protein was determined by Western blot; Cell viability was analyzed by MTT; apoptosis was analyzed by flow
cytometry (n = 3; *P,0.05).
doi:10.1371/journal.pone.0097242.g002
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[17], we could distinguish the autophagosomes and autolysosomes
through detecting both mRFP and GFP signals, followed by only
the mRFP signal. K562 cells were transfected with mRFP-GFP-
LC3 expressing pLenti6 lentivirus (Nanjing Mergene Life Science,
Nanjing, China). Autophagic flux was determined by evaluating
the punctuated pattern of GFP and mRFP (punctae/cell were
Figure 3. Overexpression of S100A8 increased the resistance of leukemia cells to chemotherapy. (A) K562 cells were transfected with
control pLPCX or pLPCX-S100A8 plasmids. Protein level of S100A8 was assayed by Western blot. (B) K562 cells transfected with control pLPCX or
pLPCX-S100A8 plasmids were treated with ADR (1 mg/mL) or VCR (1 mg/mL) for 24 hours. Apoptosis was analyzed by measuring Annexin V–positive
cells with flow cytometry (n = 3; *P,0.05). (C) K562 cells were treated as B, LC3-I/II and BECN1 levels were assayed by Western blot analysis. UT,
untreated group of K562 cells transfected with S100A8 plasmids. Control, K562 cells were transfected with control pLPCX plasmids. (D) K562 cells
were transfected with pLPCX control or pLPCX -S100A8 cDNA for 48 hours and then treated with ADR (1 mg/mL) for 24 hours in the presence or
absence of bafilomycin A1 (Baf; 100 nmol/L). The protein levels of LC3 and p62 were assayed by Western blot. (E) K562 cells were transfected pLPCX
or pLPCX-S100A8 cDNA with or without the indicated shRNA for 48 hours. Protein levels of S100A8, PI3KC3, BECN1, Atg7, LC3, and p62 were assayed
by Western blots. (F) K562 cells transfected with control pLPCX or pLPCX-S100A8 cDNA were subjected to TEM analysis. Autophagosomes were
highlighted by arrows. (G) K562 cells transfected with PLPCX-S100A8 cDNA were treated with bafilomycin A1 (Baf; 100 nmol/L) or 3-methyladenine
(3-MA; 10 mmo/L) for 12 hours. LC3 were assayed by Western blot. Control, K562 cells were transfected with control pLPCX. (H) K562 cells
transfected the indicated shRNA were treated with ADR (1 mg/mL) and VCR (1 mg/mL) for 24 hours. Cell viability was analyzed by MTT assay (n = 3;
*P,0.05). NS, not significant.
doi:10.1371/journal.pone.0097242.g003
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counted). Fluorescence was analyed on an Olympus (Aartselaar,
Belgium) cell imaging station using Cell M software. The protein
levels of LC3 and p62 were determined by Western blotting.
Transmission electron microscopic (TEM) assessment of autopha-
gosomes-like structures was performed as previously described [7].
Statistical analysis
All experiments were performed in at least triplicates per group,
and data are reported as mean6SEM, unless otherwise indicated.
Data were analyzed by 2-tailed Student t-test or ANOVA least
significant difference test, and P,0.05 was considered significant.
Results
S100A8 was overexpressed in drug resistance leukemia
cells and anticancer agents increased S100A8 expression
in leukemia cells
S100A8 was differentially expressed in different cell lines, with
relatively low S100A8 in Jurkat cells. We found that S100A8
protein was significantly increased in the drug resistance leukemia
cell line K562/A02, relative to the nondrug resistant cell line
K562 (Fig. 1A). Elevated S100A8 protein level was also observed
in the drug resistance HL-60/ADR cells compared to HL-60 cells
(Fig. 1A). Furthermore, there were relatively high levels of S100A8
mRNAs in HL-60, K562 and MV4-11 cells in comparison to
Jurkat cells (Fig. 1B), and significantly increased S100A8 mRNAs
in K562/A02 and HL-60/ADR compared with K562 and HL-60,
respectively (Fig. 1C). These results showed that drug-resistant
leukemia cells overexpress S100A8.
At the same time, we found the basal authophagy level in the
drug resistant leukemia cells was higher compared to the non-drug
resistant cell lines. We evaluated basal authophagy in leukaemia
cells and compared the levels of autophagy with S100A8
expression. Basal authophagy in leukaemia cells was low.
Moreover, we found there were no significant difference in levels
of LC3-II/LC-I in HL-60, K562 and MV4-11 cells in comparison
to Jurkat cells. However, the authophagy level were increased in
K562/A02 relative to K562, and HL-60/ADR compared to HL-
60 (Fig. 1D).
To explore the functions of S100A8 in drug resistance, we next
analyzed the relationship between the IC50 of adriamycin and the
expression level of S100A8. Increased expression of S100A8 was
correlated with higher IC50 of adriamycin (Fig. 1E). Overexpres-
sion of S100A8 in K562/A02 and HL-60/ADR cells was
coincident with dramatic increase in IC50 of adriamycin
(Fig. 1F), indicating that S100A8 plays an important role in the
drug resistance of leukemia cells.
It was reported that chemotherapeutic drugs induce S100A8 in
the supernatants of cell cultures [14]. To further determine the
Figure 4. S100A8 regulated the chemotherapy–induced autophagy in leukemia cells. (A and B) K562 cells were transfected with control
shRNA or S100A8 shRNA for 48 hours and then treated with ADR (1 mg/mL) and VCR (1 mg/mL) for 24 hours in the presence or absence of
bafilomycin A1 (Baf; 100 nmol/L). The protein levels of LC3 and p62 were assayed by Western blot (A); LC3 puncta were analyzed by LC3 antibody or
mRFP–GFP–LC3 (Magnification is 10660 oil) (B) (n = 3; *P,0.05). (C) K562 cells were transfected with control shRNA or S100A8 shRNA for 48 hours
and then treated with ADR (1 mg/mL) and VCR (1 mg/mL) for 24 hours. Autophagosome-like structures (indicated by the red arrows) were assayed by
TEM (n= 3; *P,0.05). Bar = 2 mm. (D and E) K562/A02 cells were transfected with control shRNA or S100A8 shRNA for 48 hours. After pretreatment
with rapamycin (Rap; 100 nmol/L) for 6 hours, cells were treated with ADR (1 mg/mL) for 24 hours. Apoptosis was analyzed by measuring Annexin V–
positive cells with flow cytometry (D). Autophagy was analyzed by measuring LC3 puncta formation (E; n = 3; *P,0.05).
doi:10.1371/journal.pone.0097242.g004
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potential role of S100A8 in leukemia in response to chemotherapy,
we quantified S100A8 of leukemia cells following treatment with
vincristine (VCR, 1 mg/ml), adriamycin (ADR, 1 mg/ml), and
arsenic trioxide (As2O3, 5 mM), which are widely used for the
treatment of hematological malignancies. Treatment of K562,
HL-60, Jurkat and MV4-11 cells with VCR, ADR and As2O3 for
24 h led to significant upregulation of S100A8 protein (Fig. 1G)
and mRNA (Fig. 1H).
Suppression of S100A8 rescued the chemotherapy
sensitivity in drug resistance leukemia cells
To evaluate whether overexpression of S100A8 results in drug
resistance, we knocked down S100A8 by shRNA in HL60/ADR
and K562/A02. S100A8 shRNA transfection led to a significant
decrease of both S100A8 protein and mRNA in these cells
(Fig. 2A). Knockdown of S100A8 significantly sensitized these cells
to adriamycin and Vincristine (Fig. 2B), accompanied with high
levels of apoptotic cell death (Fig. 2C) and an increase in cleaved
PARP1 (Fig. 2D). Moreover, S100A8 knockdown increased the
activation of the proapoptotic protein caspase-3 by both adria-
mycin and Vincristine, which was abolished by addition of the
pan-caspase inhibitor Z-VAD-FMK (Fig. 2E). In addition,
knockdown of S100A8 in HL60/ADR cells by another S100A8
shRNA from Gene Pharma also increased the sensitivity to DRN-
and VCR-induced suppression of cell proliferation and apoptosis
(Fig. 2F). These data demonstrated that S100A8 increased the
resistance of leukemia cells to cytotoxic agents and knockdown of
S100A8 restored the sensitivity of K562/A02 and HL60/ADR
cells to adriamycin and vincristine.
Figure 5. ULK1-mAtg13 regulated the fomation of S100A8-BECN1 complex formation in leukemia cells. (A-C) K562 cells were
transfected with S100A8 shRNA (A and B) or ULK1 shRNA (C) for 48 hours and then were treated with ADR (1 mg/mL) for 24 hours. Cells were then
processed for immunoprecipitation (IP) or Western blotting (IB) as described in Materials and Methods. All data are representative of 3 experiments.
(D) K562 cells transfected with S100A8 shRNA (A and B) or ULK1 shRNA (C) for 48 hours were treated with ADR (1 mg/mL) or VCR (1 mg/mL) for
24 hours. Apoptosis was analyzed by measuring Annexin V–positive cells with flow cytometry (n = 3; *P,0.05).
doi:10.1371/journal.pone.0097242.g005
Figure 6. Exogenous S100A8 regulate autophagy through
RAGE receptor. K562 cells were transfected with control shRNA, RAGE
shRNA or TLR4 shRNA for 48 hours, and then treated with S100A8
protein (1 mg/ml) for 24 hours. LC3, p62, RAGE and TLR4 were assayed
by Western blot. All data were representatives of 3 independent
experiments.
doi:10.1371/journal.pone.0097242.g006
S100A8 and Autophagy in Leukemia
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Overexpression of S100A8 increases the resistance of
leukemia cells to chemotherapy
To further determine the role of S100A8 in leukemia cells after
chemotherapy, we transfected K562 leukemia cells with a plasmid
containing full-length human S100A8 cDNA (Fig. 3A). Ectopic
overexpression of S100A8 in K562 cells promoted resistance to
apoptosis induced by adriamycin and vincristine (Fig. 3B).
Autophagy and apoptosis can be triggered simultaneously by
common upstream signals [18]. During autophagy, microtubule-
associated protein light chain 3 (LC3) is processed post-
translationally into soluble LC3-I, and subsequently converted to
membrane-bound LC3-II, a marker for autophagosome [19].
Overexpression of S100A8 increased LC3-II following treatment
with either ADR or VCR in K562 cells (Fig. 3C). Meanwhile,
BECN1, which is necessary for the formation of autophagosomes
during the autophagic sequestration process [20], was significantly
increased in S100A8 expressing leukemia cells treated with
adriamycin or vincristine for 24 h compared with the untreated
and control groups (Fig. 3C,D). The polyubiquitin-binding protein
SQSTM1/aequestosome 1 (p62) has LC3 binding domains, which
target p62 for incorporation into the autophagosomes, thus serving
as a selective substrate of autophagy [21]. We found that
overexpression of S100A8 increased LC3-II but decreased p62,
indicating that p62 degradation is dependent on S100A8-induced
autophagy (Fig. 3D,E). Electron microscopy analysis demonstrated
that there was increased number of multiple autophagosome-like
vacuoles with double-membrane structures in the S100A8
overexpressing cells compared with that of the control group
(Fig. 3F).
Figure 7. Scheme of S100A8-mediated autophagy promoting drug resistance in leukemia. Leukemia is the most common type of cancer
occurs in childhood. Vincristine and adriamycin are the commonly used cytotoxic anticancer drugs in the treatment of patients with Leukemia. These
drugs increase endogenous mRNA and protein expression of S100A8 in Leukemia cells by an unknown mechanism. Upregulated S100A8 competes
with BCL-2 to bind BECN1, which increases the formation of the BECN1-PtdIns3KC3 complex and stimulates autophagosome maturation and
autophagy. As an upstream signal, activation of the ULK1-mATG13 complex is required for the interaction between S100A8 and BECN1. Knockdown
of S100A8 or inhibition of autophagy increase apoptosis, and reverses drug resistance in leukemia cells. Furthermore, exogenous S100A8 regulates
autophagy through the RAGE receptor. Thus S100A8-mediated autophagy is a potential therapeutic target for leukemia.
doi:10.1371/journal.pone.0097242.g007
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We further found that increase of S100A8 during anticancer
therapy could induce autophagic flux in leukaemia cells. Accu-
mulation of LC3-II was observed in the presence of bafilomycin
A1 (an inhibitor of late phase autophagy) in k562 cells both before
and after treatment with adriamycin for 24 h compared with the
absence of bafilomycin A1 (Fig. 3D). At the same time,
overexpression of S100A8 induced autophagic p62 degradation
(Fig. 3D).
Bafilomycin A1 increased the induction of LC3-II by S100A8
(Fig 3D), whereas 3-methyladenine, an inhibitor of early-phase
autophagy [19], inhibited S100A8-induced LC3-II expression
(Fig. 3G). PI3KC3, BECN1 (the mammalian ortholog of yeast
Vps30/Atg6), and ATG7 are key regulators of the classical
autophagy pathway in mammalian cells [22]. To extend our
observation that S100A8 promotes anticancer drug resistance by
enhancing autophagy, we knocked down PI3KC3, BECN 1, and
Atg7 by shRNA and found that silencing of these genes inhibited
LC3-II formation and prevented autophagic p62 degradation in
S100A8 overexpressing K562 cells (Fig. 3E). Moreover, downreg-
ulation of these genes reversed S100A8-induced protection against
chemotherapy (Fig. 3H). These findings indicate that autophagy is
required for S100A8-mediated resistance to anticancer agents.
S100A8 regulates autophagy during chemotherapy in
leukemia cells
S100A8 is required for the initiation of As2O3-reduced
autophagy in leukemia cells [14]. To further explore the
mechanism by which S100A8 regulates autophagy in leukemia
cells, we detected LC3-I to LC3-II conversion by immunoblot
analysis and LC3 puncta formation by fluorescent imaging
analysis. Knockdown of S100A8 inhibited ADR-induced LC3-II
(Fig. 4A). LC3 is lipidated and recruited to the autophagosomal
membrane following autophagosome formation. Accordingly,
accumulation of LC3-II was observed in the presence of
bafilomycin A1 (Fig. 4A). Moreover, knockdown of S100A8
inhibited the accumulation of LC3 puncta in leukemia cells as
detected by immunofluorenscence with a LC3 antibody (Fig. 4B).
In addition, ultrastructural analysis revealed that cells transfected
with S100A8 shRNA exhibited fewer autophagosomes during
chemotherapy compared with cells transfected with control
shRNA (Fig. 4C). To test whether S100A8 influences autophagic
flux, we evaluated the expression of p62. Indeed, knockdown of
S100A8 inhibited autophagic p62 degradation (Fig. 4A). These
findings further support a critical role for S100A8 in the regulation
of autophagy in leukemia cells.
Rapamycin induces autophagy by inhibiting the mammalian
target of rapamycin complex 1 (mTORC1) [23]. Rapamycin
pretreatment prevented ADR from inducing apoptosis in K562/
A02 cells (Fig. 4D). However, rapamycin conferred less protection
in K562/A02 cells transfected with S100A8 shRNA probably due
to diminished autophagic capacity (Fig. 4E). These results suggest
that S100A8 is an important regulator of autophagy-mediated
leukemia cell survival.
S100A8 regulates the formation of BECN1–PI3KC3
complex but not ULK1–mAtg13 complex
Mammalian autophagy is a multi-step process including
initiation, nucleation, elongation, closure, maturation, and finally
degradation or extrusion, and regulated by a core family of ATG
proteins [1,24]. To explore the underlying molecular mechanism
of S100A8-mediated autophagy, we analyzed the early autophagic
signaling event of ULK1 complex formation. ULK1 is essential for
autophagy induction and is comprised of a large complex that
includes a mammalian homologue of Atg13 (mAtg13). Knock-
down of S100A8 did not affect the formation of ULK1-mAtg13
complex and phosphorylation of ULK1 at Ser55 following ADR
treatment (Fig. 5A). However, S100A8 knockdown significantly
reduced the formation of the BECN1-PI3KC3 complex (Fig. 5B),
which mediates vesicle nucleation during autophagy. Consistent
with the previous studies [14], S100A8 formed a complex with
BECN1 in leukemia cells (Fig. 5C). Moreover, knockdown of
ULK1 inhibited the interaction between S100A8 and BECN1
(Fig. 5C) and potentiated anticancer agent-induced cell apoptosis
(Fig. 5D). These data suggest that S100A8 is a downstream
signaling molecule from the ULK1-mAtg13 complex and facili-
tates autophagy in leukemia cells by interacting with BECN1.
RAGE was involved in exogenous S100A8-induced
autophagy. To investigate whether extracellular S100A8 in-
duce autophagy in leukemia cells, we treated K562 cells with
1 mg/ml S100A8 protein for 24 h and detected LC3-I/LC3-II and
P62 by immunoblot analysis. We found that S100A8 treatment
increased the expression of LC3-II, and decreased the expression
of p62. To test the role of RAGE and TLR4 in S100A8-induced
autophagy, we knocked down RAGE and TLR4 by shRNA in
K562 cells. We found that silencing RAGE inhibited LC3-II
formation and prevented autophagic p62 degradation. In contrast,
knock down of TLR4 did not influence S100A8-induced
autophagic flux. These findings indicate that RAGE is involved
in exogenous S100A8-induced autophagy (Fig. 6)
Discussion
Chemotherapy is the major treatment strategy for nearly all
types of childhood leukemia [25,26]; however, drug resistance
often renders chemotherapy ineffective and negatively impacts
long-term event-free survival [27]. Multidrug resistance results
from multiple mechanisms including dysfunctional membrane
transport, resistance to apoptosis, and the persistence of stem cell-
like leukemia cells. Thus, attenuating drug resistance is a current
challenge for the treatment of leukemia.
S100A8 is expressed in a wide variety of cell types and abundant
in myeloid cells. Elevated expression of S100A8 has been found in
disorders including rheumatoid arthritis, inflammatory bowel
disease, and vasculitis [28]. S100A8 and HMGB1 are the ligands
of receptor for advanced glycation endproducts (RAGE). RAGE/
RAGE ligand interaction is associated with survival of cells
expressing this receptor, and is involved in the development and
progression of cancer [29]. Inhibition of RAGE interaction with
S100p enhanced the anti-tumor activity of conventional chemo-
therapy in a xenograft model of pancreatic cancer [30]. We
previously found that HMGB1-induced autophagy enhances
chemotherapy resistance in leukemia cells [16]. It was reported
that S100A8 protein balances tumor cell growth and apoptosis in a
concentration-dependent manner [31]. Furthermore, variation of
S100A8 transcripts has been found in AMLs and correlates with
the FAB (French-American-British classification) subtype, or the
differentiation of AML [32]. Nevertheless, the role of S100A8 in
the pathogenesis of leukemia is unknown.
A number of anticancer therapies, including DNA-damaging
chemotherapeutic drugs, induce the accumulation of autophago-
somes in tumor cell lines, while pharmacologic inhibition of
autophagy or genetic knockdown of phylogenetically conserved
autophagy-related genes, such as Atg5 and Atg7, enhanced drug-
induced cytotoxicities [33]. The ability to affect chemotherapy
sensitivity by regulating autophagy in leukemia cells is a novel
function of S100A8 [14]. In this study, we showed that A100A8-
mediated autophagy is a significant contributor to drug resistance
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in leukemia. We found that S100A8 level was elevated in drug
resistance leukemia cells relative to the nondrug resistant cells, and
vincristine, adriamycin and arsenic trioxide enhanced the expres-
sion of S100A8 in human leukemia cells. Further, inhibition of
S100A8 or autophagy increased the drug sensitivity of leukemia
cells, and knockdown of S100A8 by shRNA increased cell death
and suppressed leukemia cell growth. As a member of DAMPs,
S100A8 demonstrate an anti-inflammatory, anti-oxidative, and
protective effect on cells [34,35]. The expression of S100A8 in
AML patients is associated with worse prognosis and a predictor of
poor survival [12]. Thus, it is intriguing to propose that release of
S100A8 by dying leukemia cells may help process and present
leukemia antigens to immune effector cells.
Cancer cells respond to chemotherapy in a variety of ways,
ranging from the activation of survival pathways to the initiation of
cell death. Increased autophagy is observed in leukemia cells when
exposed to chemotherapy drugs [5,36]. In general, autophagy is a
"programmed cell survival" mechanism to prevent the accumu-
lation of damaged or unnecessary components, but also functions
to facilitate the recycling of these components to sustain
homoeostasis. Therefore, autophagy functions as a double-edged
sword in cancer development and progression by inducing both
tumor cell survival and death. In tumor cells, the role of autophagy
may depend on the type of tumors and the stage of tumorigenesis
[37]. We found that inhibition of autophagy increases leukemia
cell death and reverses S100A8-mediated drug resistance. A
systematic study on cells exposed to many compounds showed that
no single cytotoxic agent can induce cell death by autophagy [38],
supporting the observation that autophagy is mostly a cytoprotec-
tive mechanism. Here, we found that knockdown of S100A8
decreased LC3 II formation and p62 degradation, which was
associated with a decreased number of membrane-bound
autophagosomes, as detected by TEM in leukemia cells.
We previously found that S100A8 interacts with BECN1 and
displaces Bcl-2 [14]. In the current study, we found that the
ULK1-mAtg13 complex is required for the interaction between
S100A8 and BECN1, which promotes BECN1-PI3KC3 complex
formation. However, the assembly of the BECN1 complexes is
complicated and seems to differ in a cell- or tissue-dependent
manner [39]. AMP-activated protein kinase (AMPK) is a key
molecular player in energy homeostasis and important for the
activation of ULK1 [40]. Further studies are needed to test
whether AMPK or other kinases are involved in regulating the
interaction between S100A8 and BECN1. Finally, we and found
that exogenous S100A8 regulates autophagy through its receptor,
RAGE, but not TLR4.
In conclusion, we showed that chemotherapy-induced S100A8
expression in leukemia cells promoted autophagy, which in turn
inhibited apoptosis and increased drug resistance, indicating that
S100A8 is an important regulator of autophagy. Moreover,
suppression of S100A8 expression significantly increased drug
sensitivity of leukemia cells, suggesting that S100A8 may be a
novel target for leukemia therapy. (Fig 7).
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